Endometriosis Market - Forecast(2024 - 2030)

Report Code: HCR 0853 Report Format: PDF + Excel


The Endometriosis market size is estimated to be $1.9Bn, in 2018, growing at a CAGR of 2.9% during 2019-2024. Increase focus on woman health and easy availability of patient assistance program are some of the key factors driving the endometriosis market over the forecast period, 2019 to 2024. Women with endometriosis could also have endometrial cyst which is also known as ovarian cyst. This could lead to other complications like causing chronic pelvic pain and raise the overall risk for ovarian cancer. Laparoscopy is one of the most definitive ways to do endometriosis diagnosis. The disease is often misdiagnosed with fibroid tumors and adenomyosis.

Key Takeaways

  • The ultrasound segment held the largest market share in terms of revenue with 31.01%, in 2018.
  • North America held the largest market share with 51.61%.

 By Diagnosis Type - Segment Analysis

 The endometriosis market by diagnosis type has been segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy and sonohysterography. The ultrasound segment held the largest market share in terms of revenue with 31.01%, in 2018. Rising demand for minimal invasive and non-invasive diagnostic procedures coupled with innovation in technology is a key factor resulting in the revenue share. Hysteroscopy followed ultrasound segment in terms of revenue in the same year. Laparoscopy is expected to grow the fastest over the forecast period, 2019 to 2024. 

Geography - Segment Analysis

The Endometriosis market by geography has been segmented into North America, South America, Europe, Asia Pacific and Rest of the World. North America held the largest endometriosis market share of 51.61% revenue wise, in 2018. The high prevalence of endometriosis in North America is driving market growth in the region. The high incidence rate of the disease has led to the growth in sales of hormone therapeutics to treat the condition. Vendors are also focusing on developing active hormone treatments to overcome challenges, which involves various side effects, linked with the available medications in the market. Europe followed North America in terms of revenue share in the same year. Further, Asia Pacific is expected to grow the fastest over the forecast period, 2019 to 2024.   

 Drivers – Endometriosis Market

  • Growing prevalence of endometriosis

The growing prevalence of endometriosis has led to higher awareness among the patients regarding the endometriosis treatment. Further, there is rise in focus in research and development with the increase occurrence of the disease. Moreover, government agencies are investing in healthcare infrastructure to provide better treatment facility to the patients. Thus more drugs and diagnosis equipment in line with the treatment of endometriosis are required thus driving the market further.   

  • Availability of patient assistance programs

The market is controlled by high-cost hormone-based therapeutics, which plays a significant role in the treatment of endometriosis of the patient. Thus, companies such as Bayer and AbbVie are providing patient-assistance programs which helps to reduce the cost burden on the patients. The accessibility of patient assistance programs for expensive drugs is expected to rise patient adherence to such drugs medications, which will in turn drive the market over the forecast period.

 Challenges – Endometriosis Market

  • Lack of non-invasive diagnostics

The absence of non-invasive diagnostics tests which are available in the market for endometriosis is a key factor restraining the market over the forecast period. Most people are scared, and try to avoid the pain associated with the non-invasive diagnostics procedure. However, more and more woman are being aware of the early detection of endometriosis and are non-hesitant to go forward with such diagnostics.  

Endometriosis Industry Outlook

Merger, acquisition, partnership, product innovation and focus in research and development are some of the key strategies adopted by players operating in the endometriosis market. In 2018, the market for endometriosis was fragmented with the top ten players accounting for 22.18% of the global market share. Endometriosis top 10 companies are AbbVie Inc., Abbott, Ipsen, Bayer AG, Myovant Sciences Ltd., Philogen, Pfizer, Inc., Astellas Pharma, Orphagen Pharmaceuticals, Inc. and Meditrina Pharmaceuticals.

Product development

  • On March 2018, Astellas Pharma announced the development of Opigolix (ASP 1707), a luteinizing hormone-releasing hormone receptor antagonist. The product can be used for the oral treatment of endometriosis. This product is expected to give competitive advantage to the company over other companies which are operating in the same line of business.
For more Lifesciences and Healthcare related reports, please click here

1. Endometriosis Market - Market Overview
    1.1 Definitions and Scope
2. Endometriosis Market - Executive Summary
    2.1 Market Size and Key Trends 
    2.2 Key trends by Application
    2.3 Key trends by Geography
3. Endometriosis Market – Comparative Analysis
    3.1 Product Benchmarking Key Companies
    3.2 Top 5 Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Endometriosis Market – Startup companies Scenario Premium (Premium)
    4.1 Key startup company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Market Size and Application Analysis
        4.1.4 Venture Capital and Funding Scenario
5. Endometriosis Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case studies of successful ventures
    5.4 Customer Analysis – Key companies 
6. Endometriosis Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Endometriosis Market - Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunity Analysis
    7.3 Market Life Cycle
8. Endometriosis Market – By Drug Type (Market Size -$Million/$Billion)
    8.1 Gonadotropins releasing hormone agonists
    8.2 Non-steroidal anti-inflammatory drugs
    8.3 Progestin
    8.4 Oral contraceptive pills
9. Endometriosis Market – By Diagnosis Type (Market Size -$Million/$Billion)
    9.1 Ultrasound
    9.2 Pelvic Exam
    9.3 Laparoscopy
    9.4 Magnetic Resonance Imaging (MRI)
    9.5 Hysteroscopy
    9.6 Sonohysterography
10. Endometriosis Market – By Treatment Type (Market Size -$Million/$Billion)
    10.1 Hormonal Therapy
    10.2 Pain Management
11. Endometriosis Market – By Distribution Channel (Market Size -$Million/$Billion)
    11.1 Hospital Pharmacies
    11.2 Drug Stores
    11.3 Retail Pharmacies
    11.4 Mail Order Pharmacies
    11.5 E-Commerce
12. Endometriosis Market – By Geography (Market Size -$Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France 
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Australia 
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 India
        12.3.6 Rest of Asia Pacific
    12.4 RoW
        12.4.1 Middle East
        12.4.2 Africa
13. Endometriosis Market – Entropy
14. Endometriosis Market - Industry / Segment Competition landscape Premium (Premium)
    14.1 Market Share Analysis
        14.1.1 Market Share by Country- Key companies
        14.1.2 Market Share by Region- Key companies
        14.1.3 Market Share at Global level- Key companies
        14.1.4  Best Practices for companies
15. Endometriosis Market - Key Company List by Country Premium (Premium)
16. Endometriosis Market - Company Analysis
    16.1 Market Share, Company Revenue, Products, M&A, Developments
        16.1.1 Company 1
        16.1.2 Company 2
        16.1.3 Company 3
        16.1.4 Company 4
        16.1.5 Company 5
        16.1.6 Company 6
        16.1.7 Company 7
        16.1.8 Company 8
        16.1.9 Company 9
        16.1.10 Company 10 and more
"*Financials of the private companies would be provided on a best efforts basis”